EU Authorizes Alzheimer‘s Drug “Lecanemab”

Bonn/Germany, April 15, 2025. The European Commission has granted authorization of the Alzheimer’s drug “Lecanemab” (brand name: Leqembi). The novel medicine is indicated for the treatment of early Alzheimer's and can slow down the progression of the disease. Lecanemab is an engineered antibody that targets so-called amyloid proteins, which accumulate in the brain in Alzheimer’s disease. Prof. Dr. Gabor Petzold, a neurologist and Director of Clinical Research at DZNE comments on the current...